NASDAQ$SY
So-Young International Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
So-Young International reported Q1 2025 total revenues of $41.0M with a net loss of $4.6M.
Total revenues were RMB297.3 million (US$41.0 million), at the high end of prior guidance but down year over year as the platform transitions toward owned aesthetic centers. Net loss attributable to So-Young was US$4.6 million; non-GAAP net loss was US$4.3 million versus modest non-GAAP profit a year ago.
- Q1 revenue US$41.0M (RMB297.3M).
- Net loss US$4.6M amid center expansion.
- 23 aesthetic centers operating in nine Chinese cities.
- Treatment services revenue growing with center rollout.
Headline financials
Revenue & EPS history
So-Young · Revenue · Quarterly
$41M
Revenue by segment
So-Young · $433M total across 4 segments · Q1 2026
- Aesthetic treatment services$282M—65.3%
- Information and reservation services$80.3M—18.6%
- Sales of medical products and maintenance services$57.1M—13.2%
- Other services$12.9M—3.0%
Forward guidance
Biotech outlook emphasizes pipeline milestones, collaboration funding, and cash runway.
Tailwinds
- Partnership revenue and milestone potential.
- Clinical progress on lead programs.
Headwinds
- Operating losses and dilution risk.
- Regulatory and trial execution uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-2.1%
Avg return
Earnings day
-3.5%
Avg return
5 days after
-4.5%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+23.6%
Q4 2022
Best reaction
-27.7%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q4 2025 | +9.6% | -11.0% | -6.5% | |
| Q3 2025 | -8.4% | -17.2% | -23.2% | |
| Q2 2025 | -22.7% | -16.1% | -22.1% | |
| Q1 2025 | +1.4% | +7.3% | +18.4% | |
| Q4 2024 | -9.6% | -5.3% | -13.7% | |
| Q3 2024 | +1.0% | -2.4% | -13.5% | |
| Q2 2024 | -4.6% | +0.6% | -16.6% | |
| Q1 2024 | -1.9% | +1.9% | +0.0% | |
| Q4 2023 | +0.0% | +1.0% | +11.5% | |
| Q3 2023 | +6.0% | +0.9% | +6.8% | |
| Q2 2023 | +10.7% | +9.9% | -6.6% | |
| Q1 2023 | -9.3% | -10.9% | -20.2% | |
| Q4 2022 | +23.6% | +31.5% | +64.5% | |
| Q3 2022 | +6.5% | +6.6% | +80.3% | |
| Q2 2022 | -6.2% | -13.7% | -2.2% | |
| Q1 2022 | -13.0% | +2.6% | -20.6% | |
| Q4 2021 | -5.9% | -5.0% | -33.9% | |
| Q3 2021 | +7.1% | -4.4% | -26.4% | |
| Q2 2021 | -9.2% | -10.6% | -16.2% | |
| Q1 2021 | -4.3% | +0.7% | +2.3% | |
| Q4 2020 | -16.5% | -19.9% | -24.0% | |
| Q3 2020 | -10.3% | -16.1% | -24.9% | |
| Q2 2020 | +6.9% | +2.2% | +0.0% | |
| Q1 2020 | +1.5% | -12.1% | -3.9% | |
| Q4 2019 | +12.8% | +15.1% | +18.4% | |
| Q3 2019 | -2.2% | -4.3% | +1.0% | |
| Q2 2019 | -27.7% | -33.4% | -43.0% | |
| Q1 2019 | +6.7% | +5.5% | -10.5% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro